Back to Home
Free CE/CMEVideo

Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Release Date

December 22, 2025

Expiration Date

December 23, 2026

Credits

1.0 CME, NCPD, CPE

Specialties

Critical Care, General Oncology+6 more

Release Date: December 22, 2025

CME Track Expiration Date: December 22, 2026

Pharmacist Track Expiration Date: March 31, 2027

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the recognition, prevention, and management of oncologic emergencies associated with high-dose methotrexate (HDMTX) treatment. In this educational program, these experts discuss the latest updates in the management of HDMTX, practical strategies for delayed clearance, and toxicity management .

This educational activity is an archive of the live symposium held on December 17, 2025.

Target Audience

This educational activity is directed toward oncologists, hematologists, pharmacists, advanced practice providers (nurse practitioners and physician assistants), and other health care professionals involved in the care of patients receiving high-dose methotrexate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine supportive care requirements for patients with cancer receiving treatment with high-dose methotrexate (HDMTX)
  • Integrate online clinical support tools such as mtxpk.org to aid identification of delayed methotrexate clearance
  • Apply guideline-based recommendations to manage oncologic emergencies in patients with delayed methotrexate clearance following HDMTX administration
Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Physicians' Education Resource®, LLC, has approved this application-based activity for 1.00 ACPE CE hours UAN # 0661-0000-25-028-H05-P. Eligibility for credits requires full engagement with the enduring activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre/post-session questions, and the post activity evaluation. This UAN # expires 3/31/2027.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from SERB Pharmaceuticals.

Related Content

View All

Course

Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Create Account